Chemical Compound

Carfilzomib

CAS Registry Number 868540-17-4

Back to search Request a Quote

Primary Record

Carfilzomib

In stock: 6,203 g
Purity: 99.1 %
CAS: 868540-17-4

Compound Identifiers & Properties

CAS: 868540-17-4
PubChem CID: 11556711
SMILES: CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1

Names & Synonyms

Carfilzomib
Kyprolis
868540-17-4
Carfilzomib (PR-171)
carfilzomibum
PR-171
Carfilzomib [USAN]
Kyprolis (TN)
Carfilzomib (PR171)
Carfilzomib(PR171)
Carfilzomib; PR171
Carfilzomib (Standard)
UNII-72X6E3J5AR
Carfilzomib [USAN:INN]
RefChem:57059
CARFILZOMIB [MI]
72X6E3J5AR
CARFILZOMIB [INN]
CARFILZOMIB [JAN]
DTXSID4048690
D00UVA
CARFILZOMIB [VANDF]
Carfilzomib (PR-171)?
CHEMBL451887
C40H57N5O7
MFCD11040997
SCHEMBL85165
CARFILZOMIB [WHO-DD]
DTXCID0028616
cc-684
CHEBI:65347
MLS006011102
NSC-758252
Carfilzomib (JAN/USAN/INN)
GTPL7420
orb1307429
PR171
QCR-96
Carfilzomib?PR-171?/Kyprolis
AMY4357
CARFILZOMIB [ORANGE BOOK]
L01XX45
BLMPQMFVWMYDKT-NZTKNTHTSA-N
GLXC-90068
AOB87759
EX-A2037
KS-00000SR1
ONO-7057
Tox21_113079
AN-217
BDBM50277889
EBC-17178
HY-10455R
NCGC00249613-01
NSC756640
NSC758252
PR 171
s2853
ZINC49841054
AKOS025401910
Tox21_113079_1
ACN-039824
CCG-270405
CS-0984
CS-W004540
DB08889
FC46443
NSC 758252
NSC-756640
RL05381
CID11556711
NCGC00249613-02
NCGC00249613-03
NCGC00249613-08
NCGC00249613-11
NCGC00249613-13
AC-27051
AK546882
AS-17059
BC251806
BP-43632
CID 11556711
CID:11556711
HY-10455
SC-91032
SMR004660024
SY068813
SID:124360326
AB0008111
CAS-868540-17-4
NS00072616
PX-171-007
SW218090-2
Y0441
J2.711.864J
A11278
D08880
S-7798
AB01565867_02
A904242
C524865
F951459
SR-01000941582
(alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
SR-01000941582-1
BRD-K15179879-001-03-2
Q15366934
(S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide
B0084-305419
(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
(2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide
(S)-4-methyl-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
Carfilzomib, 99%, irreversible proteasome inhibitor - 100MG 100mg
(2S)-N-[(1S)-1-benzyl-2-[[(1S)-3-methyl-1-[(2R)-2-methyloxirane-2-carbonyl]butyl]amino]-2-oxo-ethyl]-4-methyl-2-[[(2S)-2-[(2-morpholinoacetyl)amino]-4-phenyl-butanoyl]amino]pentanamide
(S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide
L-Phenylalaninamide, (alphaS)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-L-leucyl-N-((1S)-3-methyl-1-(((2R)-2-methyloxiranyl)carbonyl)butyl)-
(|AS)-|A-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
(2R)-2-Methyl-2-[N-[(2S)-2-[(morpholinoacetyl)amino]-4-phenylbutyryl]-L-Leu-L-Phe-L-Leu-]oxirane
(2S)-4-methyl-N-[(1S)-1-{[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]carbamoyl}-2-phenylethyl]-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]-4-phenylbutanamido]pentanamide
(2S)-N-[(1S)-1-Benzyl-2-[[(1S)-3-methyl-1-[[(2R)-2-methyloxiran-2-yl]carbonyl]butyl]amino]-2-oxoethyl]-4-methyl-2-[[(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
(alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phenylalaninamide
(aS)-a-[(4-Morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-phenylalani namide
(S)-4-Methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbu
(S)-4-Methyl-N-[(S)-1-[[(S)-4-methyl-1-[(R)-2-methyloxiran-2-yl]-1-oxo-2-pentyl]amino]-1-oxo-3-phenyl-2-propyl]-2-[(S)-2-(2-morpholinoacetamido)-4-phenylbutanamido]pentanamide
L-PHENYLALANINAMIDE, (.ALPHA.S)-.ALPHA.-((4-MORPHOLINYLACETYL)AMINO)BENZENEBUTANOYL-L-LEUCYL-N-((1S)-3-METHYL-1-(((2R)-2-METHYLOXIRANYL)CARBONYL)BUTYL)-
L-Phenylalaninamide, (aS)-a-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-; L-Phenylalaninamide, (aS)-a-[(4-morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]- (9CI); (aS)-a-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide; Carfilzomib; Kyprolis; PR 171
N-((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)-L-leucyl-N-((2S)-4-methyl-1-((2R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-L-phenylalaninamide
N-(Morpholinoacetyl)-4-phenyl-L-Abu-L-Leu-L-Phe-[(S)-3-methyl-1-[[(R)-2-methyloxiranyl]carbonyl]butyl]NH2
N-{(2S)-2-[2-(Morpholin-4-yl)acetamido]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide